Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Return on Equity (2021 - 2025)

Historic Return on Equity for Vivos Therapeutics (VVOS) over the last 5 years, with Q3 2025 value amounting to 4.82%.

  • Vivos Therapeutics' Return on Equity fell 30200.0% to 4.82% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.82%, marking a year-over-year decrease of 30200.0%. This contributed to the annual value of 2.68% for FY2024, which is 25500.0% up from last year.
  • Per Vivos Therapeutics' latest filing, its Return on Equity stood at 4.82% for Q3 2025, which was down 30200.0% from 3.2% recorded in Q2 2025.
  • Vivos Therapeutics' 5-year Return on Equity high stood at 0.56% for Q3 2021, and its period low was 59.63% during Q4 2023.
  • Over the past 5 years, Vivos Therapeutics' median Return on Equity value was 2.04% (recorded in 2022), while the average stood at 7.37%.
  • As far as peak fluctuations go, Vivos Therapeutics' Return on Equity plummeted by -563800bps in 2023, and later surged by 582000bps in 2024.
  • Quarter analysis of 5 years shows Vivos Therapeutics' Return on Equity stood at 0.7% in 2021, then plummeted by -365bps to 3.25% in 2022, then crashed by -1733bps to 59.63% in 2023, then skyrocketed by 98bps to 1.43% in 2024, then tumbled by -237bps to 4.82% in 2025.
  • Its Return on Equity stands at 4.82% for Q3 2025, versus 3.2% for Q2 2025 and 1.83% for Q1 2025.